Table 1

Baseline characteristics at ABA initiation across nine European registries

RegistersFollow-up (pt-years)Folllow-up /ptMale %Age (years)RF %Anti-CCP %Disease duration (years)HAQ*DAS28BMI (kg/m2)CRP (mg/L)ESR (mm/h)sDMARDs (n)bDMARDs (n)Median year of ABA initiation
Combined(3961 pts)61881.1(0.5–2.4)19.457.3±13.076.868.311.3±8.11.3±0.75.0±1.326.0±5.122.2±34.231.6±24.42.4±1.8 2 (1–3)1.8±1.4 2 (1–3)2009
ARTIS(1019 pts)16151.0(0.5–2.1)20.758.6±12.4__9.6±3.91.3±0.75.1±1.324.8±1.519.6±26.530.4±23.01.6±1.0 1 (1–2)1.9±1.3 2 (1–3)2011
ATTRA(215 pts)3561.2(0.6–2.6)20.950.1±12.570.174.711.2±7.71.5±0.55.7±1.125.5±4.925.7±29.338.3±24.33.7±1.7 4 (2–5)__2010
BIOBADASER(283 pts)5071.5(0.7–2.5)18.456.6±13.183.76012.1±8.41.7±0.75.1±1.6_18.1±26.033.6±27.7±2.3±1.9 2 (1–3)2010
DANBIO(315 pts)4370.8(0.4–2.0)19.056.0±12.584.359.311.4±9.61.4±0.74.9±1.226.3±5.618.3±26.2_4.3±2.2 4 (3–6)1.4±1.1 1 (1–2)2010
GISEA(375 pts)5031.1(0.5–2.0)13.356.5±12.573.681.710.6±8.41.4±0.85.0±1.125.8±5.039.0±66.034.4±23.42.5±1.5 2 (2–3)1.4±1.0 1 (1–2)2010
NOR-DMARD(52 pts)540.7(0.4–1.1)11.551.3±12.559.648.914.8±9.70.9±0.55.4±1.124.0±4.124.2±34.236.4±28.13.2±1.5 3 (2–4)2.3±1.1 2 (2–3)2009
ORA(1019 pts)18321.4(0.6–2.9)20.858.2±13.671.269.713.6±9.51.2±0.75.3±1.2_25.1±32.835.5±27.73.1±1.8 3 (2–4)2.3±1.3 2 (1–3)2008
REUMA.PT (37 pts)481.2(0.5–1.6)13.559.0±14.157.151.612.3±8.31.6±0.75.5±1.627.2±5.715.4±15.440.6±24.81.6±1.1 1 (1–3)2.0±1.3 2 (1–3)2010
SCQM(646 pts)8350.9(0.4–1.7)20.057.8±12.572.667.010.0±8.91.0±0.74.1±1.426.0±5.112.0±16.223.4±19.71.0±1.1 1 (0–2)1.2±1.2 1 (0–2)2010
  • *Values are means±SD and median [IQR], unless otherwise noted.

  • ABA, abatacept; BMI, body mass index; bDMARDs, biological disease modifying antirheumatic drugs; CCP, CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; pts, patients; RF, rheumatoid factor; sDMARDs, synthetic DMARDs.